# PathToScale: The PERSIST Trial

> **NCT07221747** · NA · RECRUITING · sponsor: **Georgetown University** · enrollment: 9900 (estimated)

## Conditions studied

- Oral Pre-exposure Prophylaxis (PrEP)
- Long-acting Injectable Cabotegravir for PrEP

## Interventions

- **BEHAVIORAL:** Standard of Care (SoC)
- **BEHAVIORAL:** Enhanced continuation support package

## Key facts

- **NCT ID:** NCT07221747
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-16
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-11
- **Target enrollment:** 9900 (ESTIMATED)
- **Last updated:** 2026-03-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07221747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07221747, "PathToScale: The PERSIST Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07221747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*